Alpha Lipoic Acid: Alpha lipoic acid is a coenzyme that is a very potent antioxidant
NKTCL cell lines treated with ARQ197, an ATP-non-competitive selective c-MET inhibitor which is currently in phase 3 clinical trials in NSCLC patients, reduced the proliferative response by approximately 50% in two of three cell lines, indicating that the HGF/c-MET signaling is partly responsible for NKTCL proliferation [49]
They include megaloblastic anemia, lethargy, failure to thrive, microcephaly, brain abnormalities, developmental delay, intellectual deficit, seizures, and retinopathy
The main caveat: community doses cluster well below the 12 mg trial peak, so trial percentages are not directly applicable
Tarrag, E.N
The evidence base for optimal supportive care and interventions in ARDS patients continues to evolve to address areas of uncertainty